Nektar Therapeutics
NKTR
241 hedge funds and large institutions have $2.35B invested in Nektar Therapeutics in 2021 Q4 according to their latest regulatory filings, with 29 funds opening new positions, 83 increasing their positions, 74 reducing their positions, and 39 closing their positions.
100% more funds holding in top 10
Funds holding in top 10: 1 → 2 (+1)
38% more call options, than puts
Call options by funds: $33.8M | Put options by funds: $24.5M
34% more capital inflows, than outflows
Capital inflows: $287M | Capital outflows: $214M
12% more repeat investments, than reductions
Existing positions increased: 83 | Existing positions reduced: 74
3.11% more ownership
Funds ownership: 91.23% → 94.34% (+3.1%)
0% more funds holding
Funds holding: 241 → 241 (0)
26% less first-time investments, than exits
New positions opened: 29 | Existing positions closed: 39
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$113M |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$20.3M |
| 3 |
Invesco
Atlanta,
Georgia
|
+$17.6M |
| 4 |
Woodline Partners
San Francisco,
California
|
+$14.3M |
| 5 |
State Street
Boston,
Massachusetts
|
+$9.29M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$105M |
| 2 |
DFO
Duquesne Family Office
New York
|
-$18M |
| 3 |
Primecap Management
Pasadena,
California
|
-$8.2M |
| 4 |
Great Point Partners
Greenwich,
Connecticut
|
-$7.3M |
| 5 |
Northern Trust
Chicago,
Illinois
|
-$7.01M |
NKTR Hedge Fund Activity: Q4 2021 in Review
241 of the 6,518 institutional investors tracked by Wall St. Rank reported a position in Nektar Therapeutics (NKTR) for Q4 2021, worth a combined $2.35B — down 22% from $3.01B a quarter earlier.
Sellers outnumbered buyers: 39 funds closed out of NKTR and 29 opened new positions — a net loss of 10 holders — while 74 trimmed existing stakes and 83 added.
The largest buyer was BlackRock, adding an estimated $113M. The largest seller was Fidelity Investments, cutting an estimated $105M.
- 241 institutional investors held Nektar Therapeutics (NKTR) as of Q4 2021, unchanged from Q3 2021.
- Funds reported $2.35B of Nektar Therapeutics stock for Q4 2021, down 22% quarter-over-quarter.
- 29 funds opened new Nektar Therapeutics positions in Q4 2021 and 39 closed out, a net change of -10 holders.
- The largest Nektar Therapeutics buyer in Q4 2021 was BlackRock, an estimated $113M added.
- The largest Nektar Therapeutics seller in Q4 2021 was Fidelity Investments, an estimated $105M sold.
Based on aggregated 13F filings for Q4 2021.